Loading...

Infinity Pharmaceuticals

DB:I3F
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
I3F
DB
$86M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Infinity Pharmaceuticals has significant price volatility in the past 3 months.
I3F Share Price and Events
7 Day Returns
-9.3%
DB:I3F
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-25.7%
DB:I3F
-10.6%
DE Biotechs
-6.2%
DE Market
I3F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Infinity Pharmaceuticals (I3F) -9.3% -11.7% 23% -25.7% -76.5% -80.1%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • I3F underperformed the Biotechs industry which returned -10.6% over the past year.
  • I3F underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
I3F
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Infinity Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Infinity Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Infinity Pharmaceuticals.

DB:I3F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:I3F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 21%) (0%))
1.301
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.301 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:I3F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Infinity Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:I3F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -12.00 Analyst x1 -11.11
2020 -47.16 Analyst x2 -40.45
2021 -50.16 Analyst x1 -39.84
2022 -14.68 Analyst x1 -10.80
2023 126.93 Analyst x1 86.46
2024 210.03 Est @ 65.47% 132.49
2025 306.43 Est @ 45.9% 179.02
2026 405.10 Est @ 32.2% 219.17
2027 496.68 Est @ 22.61% 248.86
2028 575.62 Est @ 15.89% 267.09
Present value of next 10 years cash flows $1,030.90
DB:I3F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $575.62 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$7,441.42
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $7,441.42 ÷ (1 + 7.98%)10
$3,452.90
DB:I3F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,030.90 + $3,452.90
$4,483.79
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,483.79 / 56.93
$78.77
DB:I3F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:I3F represents 0.83822x of NasdaqGS:INFI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.83822x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 78.77 x 0.83822
€66.02
Value per share (EUR) From above. €66.02
Current discount Discount to share price of €1.32
= -1 x (€1.32 - €66.02) / €66.02
98%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Infinity Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €1.32 vs Future cash flow value of €66.02
Current Discount Checks
For Infinity Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Infinity Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Infinity Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Infinity Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Infinity Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:I3F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.20
NasdaqGS:INFI Share Price ** NasdaqGS (2019-04-23) in USD $1.57
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Infinity Pharmaceuticals.

DB:I3F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:INFI Share Price ÷ EPS (both in USD)

= 1.57 ÷ -0.20

-7.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Infinity Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Infinity Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Infinity Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:I3F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
32.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Infinity Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Infinity Pharmaceuticals's assets?
Raw Data
DB:I3F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.92
NasdaqGS:INFI Share Price * NasdaqGS (2019-04-23) in USD $1.57
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:I3F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:INFI Share Price ÷ Book Value per Share (both in USD)

= 1.57 ÷ 0.92

1.7x

* Primary Listing of Infinity Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Infinity Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Infinity Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Infinity Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Infinity Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Infinity Pharmaceuticals expected to grow at an attractive rate?
  • Infinity Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Infinity Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Infinity Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:I3F Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:I3F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 32.6%
DB:I3F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 42.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:I3F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:I3F Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 236 144 142 1
2022-12-31 72 -1 -7 1
2021-12-31 9 -39 -51 1
2020-12-31 1 -42 -61 4
2019-12-31 18 -13 -24 4
DB:I3F Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 22 -5 -11
2018-09-30 22 -20 -10
2018-06-30 6 -24 -31
2018-03-31 6 -29 -41
2017-12-31 6 -37 -42
2017-09-30 6 -59 -57
2017-06-30 0 -83 -70
2017-03-31 9 -120 0
2016-12-31 19 -154 -30
2016-09-30 28 -51 -46
2016-06-30 119 -50 15
2016-03-31 114 -36 -76

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Infinity Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Infinity Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:I3F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Infinity Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:I3F Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.08 2.08 2.08 1.00
2022-12-31 -0.10 -0.10 -0.10 1.00
2021-12-31 -0.80 -0.80 -0.80 1.00
2020-12-31 -0.97 -0.70 -1.49 4.00
2019-12-31 -0.49 -0.30 -0.63 3.00
DB:I3F Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.20
2018-09-30 -0.19
2018-06-30 -0.59
2018-03-31 -0.80
2017-12-31 -0.83
2017-09-30 -1.14
2017-06-30 -1.39
2017-03-31 0.00
2016-12-31 -0.61
2016-09-30 -0.94
2016-06-30 0.31
2016-03-31 -1.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Infinity Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Infinity Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Infinity Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Infinity Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Infinity Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Infinity Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Infinity Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Infinity Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Infinity Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Infinity Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:I3F Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 22.15 -11.25 14.25
2018-09-30 22.00 -10.33 14.90
2018-06-30 6.00 -30.82 15.97
2018-03-31 6.00 -40.81 18.78
2017-12-31 6.00 -41.83 21.62
2017-09-30 6.00 -57.46 23.82
2017-06-30 0.00 -69.61 25.43
2017-03-31 9.47 0.09 30.22
2016-12-31 18.72 -30.10 34.62
2016-09-30 27.80 -46.36 37.30
2016-06-30 118.55 15.44 40.93
2016-03-31 113.96 -75.74 39.35
2015-12-31 109.07 -128.38 37.07
2015-09-30 104.34 -129.17 35.10
2015-06-30 174.24 -70.57 33.38
2015-03-31 169.36 -68.45 31.03
2014-12-31 165.00 -17.42 29.29
2014-09-30 160.64 -10.36 28.40 99.76
2014-06-30 0.00 -145.44 27.67 99.76
2014-03-31 -141.72 27.29 99.76
2013-12-31 -126.78 27.92
2013-09-30 0.00 -140.84 27.34 73.60
2013-06-30 0.00 -88.50 26.31 73.60
2013-03-31 21.91 -70.57 27.30 73.60
2012-12-31 47.11 -53.96 26.68 73.60
2012-09-30 69.44 -21.04 26.82 20.08
2012-06-30 92.74 -51.39 25.99 20.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Infinity Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Infinity Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Infinity Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Infinity Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Infinity Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Infinity Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Infinity Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Infinity Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Infinity Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Infinity Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Infinity Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Infinity Pharmaceuticals Company Filings, last reported 3 months ago.

DB:I3F Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 52.46 0.00 58.59
2018-09-30 59.77 0.00 42.17
2018-06-30 45.56 0.00 49.17
2018-03-31 45.40 0.00 47.81
2017-12-31 47.73 6.00 57.61
2017-09-30 53.37 6.00 55.58
2017-06-30 58.90 0.00 66.20
2017-03-31 73.79 0.00 75.43
2016-12-31 82.45 0.00 92.06
2016-09-30 102.12 0.00 112.30
2016-06-30 118.83 0.00 146.39
2016-03-31 61.65 0.00 192.97
2015-12-31 98.56 0.00 245.23
2015-09-30 133.61 0.00 162.96
2015-06-30 87.26 0.00 199.48
2015-03-31 121.08 0.00 233.05
2014-12-31 209.47 6.67 332.73
2014-09-30 245.52 6.61 379.00
2014-06-30 138.49 6.56 141.16
2014-03-31 173.05 6.51 171.53
2013-12-31 201.28 13.12 213.89
2013-09-30 230.26 13.02 250.30
2013-06-30 259.91 12.91 276.68
2013-03-31 289.37 0.00 302.57
2012-12-31 310.21 12.71 326.02
2012-09-30 179.73 0.00 188.77
2012-06-30 -3.39 38.93 103.91
  • Infinity Pharmaceuticals has no debt.
  • Infinity Pharmaceuticals has no debt compared to 5 years ago when it was 6.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Infinity Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Infinity Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -41.1% each year.
X
Financial health checks
We assess Infinity Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Infinity Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Infinity Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Infinity Pharmaceuticals dividends.
If you bought €2,000 of Infinity Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Infinity Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Infinity Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:I3F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:I3F Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Infinity Pharmaceuticals has not reported any payouts.
  • Unable to verify if Infinity Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Infinity Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Infinity Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Infinity Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Infinity Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Infinity Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Infinity Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Adelene Perkins
COMPENSATION $2,528,450
AGE 58
TENURE AS CEO 9.3 years
CEO Bio

Ms. Adelene Q. Perkins has been the Chief Executive Officer of Infinity Pharmaceuticals, Inc. since January 2, 2010 and has been its Chairman since November 2012. Ms. Perkins served as the President of Infinity Pharmaceuticals, Inc. from October 2008 to January 4, 2017. She has more than 30 years of international business and corporate strategy experience in the biopharmaceutical industry, focused on licensing and business development, strategic finance, product life cycle management and leading high-caliber, cross-functional teams. Ms. Perkins served as Principal Financial Officer of Infinity Pharmaceuticals, Inc. and is responsible for all of Infinity's business functions, including corporate and product strategy, business development, finance, organizational development and human resources, investor and public relations, legal and facilities and operations. Ms. Perkins served as the Chief Business Officer of Infinity Pharmaceuticals Inc. from October 2008 through December 2009. She served as Executive Vice President of Infinity Pharmaceuticals Inc since September 2006 until October 2008. Ms. Perkins served as Executive Vice President of Infinity Discovery, Inc., from February 2006 until the merger with our predecessor company in September 2006 and Chief Business Officer of Infinity Discovery from June 2002 until September 2006. She joined Infinity from TransForm Pharmaceuticals where she served as Vice President of Business and Corporate Development from 2000 to 2002. An early Member of TransForm’s management team, she played an instrumental role in building it, including setting strategic and operational priorities, recruiting senior management and establishing TransForm’s first major strategic alliances with large pharmaceutical partners. From 1992 to 1999, Ms. Perkins was at Genetics Institute, a unit of Wyeth, where she served as Vice President of Emerging Businesses with a mandate to identify and capitalize on opportunities to create value in new business ventures. In this role, she Co-founded and served as General Manager of the DiscoverEase™ Business Unit where she was responsible for building and managing a 100-person scientific and business unit that generated a library of over 800 novel genes that encode for secreted proteins which was partnered with over 50 corporate and academic partners. Ms. Perkins formed and served as the Chief Executive Officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University directed at discovering and developing members of the TGF-b superfamily. She joined Genetics Institute in Corporate and Business Development where she worked with the Executive Committee to develop corporate, product and research strategies where she was responsible for numerous business development transactions both in- and out-licensing technologies and products. From 1985 to 1992, Ms. Perkins was at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry, including providers, insurers, investors and pharmaceutical companies. She managed Bain’s internal strategy initiative, which identified the need for industry practice areas, including the formation of its health care practice. She has been a Director of Infinity Pharmaceuticals, Inc. since January 2, 2010. She has been Director at Bruker Corporation since May 22, 2017. She served as Independent Director at Padlock Therapeutics, Inc. from October 2015 to 2016. She is on the Board of the Villanova University College of Engineering Advisory Board. She serves on the Boards of BIO (Biotechnology Industry Organization) since 2012, Massachusetts General Hospital, the Massachusetts Life Sciences Center and the Massachusetts Biotechnology Council; she is the Vice Chairman of the Board of Project Hope. Ms. Perkins holds an MBA from Harvard Business School and a BS in Chemical Engineering from Villanova University.

CEO Compensation
  • Adelene's compensation has increased whilst company is loss making.
  • Adelene's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Infinity Pharmaceuticals management team in years:

2.3
Average Tenure
51
Average Age
  • The tenure for the Infinity Pharmaceuticals management team is about average.
Management Team

Adelene Perkins

TITLE
Chairman & CEO
COMPENSATION
$3M
AGE
58
TENURE
9.3 yrs

Larry Bloch

TITLE
President & Treasurer
COMPENSATION
$2M
AGE
52
TENURE
2.3 yrs

Jeff Kutok

TITLE
Senior VP & Chief Scientific Officer
COMPENSATION
$1M
AGE
51
TENURE
2.2 yrs

Seth Tasker

TITLE
VP, General Counsel & Secretary
COMPENSATION
$1M
AGE
39
TENURE
2.8 yrs

Melissa Hackel

TITLE
Vice President of Finance
TENURE
2.3 yrs

Sam Agresta

TITLE
Chief Medical Officer
AGE
45
TENURE
0.7 yrs

Jayne Kauffman

TITLE
Senior Executive Coordinator
Board of Directors Tenure

Average tenure and age of the Infinity Pharmaceuticals board of directors in years:

2
Average Tenure
64
Average Age
  • The average tenure for the Infinity Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Adelene Perkins

TITLE
Chairman & CEO
COMPENSATION
$3M
AGE
58
TENURE
6.4 yrs

Tony Evnin

TITLE
Director
COMPENSATION
$130K
AGE
77
TENURE
12.6 yrs

Norman Selby

TITLE
Lead Independent Director
COMPENSATION
$172K
AGE
66

Mike Venuti

TITLE
Director
COMPENSATION
$130K
AGE
64
TENURE
15.9 yrs

Jeff Berkowitz

TITLE
Independent Director
COMPENSATION
$115K
AGE
52
TENURE
5.1 yrs

Michael Kauffman

TITLE
Independent Director
COMPENSATION
$136K
AGE
55
TENURE
2 yrs

David Beier

TITLE
Director
AGE
69
TENURE
1 yrs

Dmitry Gabrilovich

TITLE
Member of Scientific Advisory Board
TENURE
1.1 yrs

Roy Herbst

TITLE
Member of Scientific Advisory Board
TENURE
1.1 yrs

David Munn

TITLE
Member of Scientific Advisory Board
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Dec 18 Buy BVF Partners LP Company 13. Dec 18 13. Dec 18 175,000 €1.06 €184,870
30. Nov 18 Buy BVF Partners LP Company 28. Nov 18 28. Nov 18 100,000 €1.15 €115,219
21. Nov 18 Sell BVF Partners LP Company 13. Nov 18 13. Nov 18 -604,208 €1.20 €-722,775
21. Nov 18 Buy BVF Partners LP Company 14. Nov 18 19. Nov 18 148,150 €1.20 €175,891
21. Nov 18 Buy BVF Partners LP Company 19. Nov 18 21. Nov 18 1,469,826 €1.20 €1,764,620
16. Nov 18 Buy BVF Partners LP Company 13. Nov 18 15. Nov 18 905,932 €1.19 €1,079,159
21. Jun 18 Buy BVF Partners LP Company 19. Jun 18 21. Jun 18 3,942,091 €1.42 €5,606,836
21. Jun 18 Buy BVF Partners LP Company 21. Jun 18 21. Jun 18 13,669 €1.42 €19,441
X
Management checks
We assess Infinity Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Infinity Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Details
Name: Infinity Pharmaceuticals, Inc.
I3F
Exchange: DB
Founded:
$76,708,515
56,925,528
Website: http://www.infi.com
Address: Infinity Pharmaceuticals, Inc.
784 Memorial Drive,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS INFI Common Shares Nasdaq Global Select US USD 13. Sep 2006
DB I3F Common Shares Deutsche Boerse AG DE EUR 13. Sep 2006
Number of employees
Current staff
Staff numbers
25
Infinity Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:02
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/05
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.